STOCK TITAN

Ocean Biomedical Inc. - OCEA STOCK NEWS

Welcome to our dedicated news page for Ocean Biomedical (Ticker: OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocean Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocean Biomedical's position in the market.

Rhea-AI Summary
Ocean Biomedical, Inc. received a notice from Nasdaq regarding the late filing of its Annual Report on Form 10-K for the period ended December 31, 2023. The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) and must submit a plan to regain compliance by June 14, 2024, and file the delinquent Form 10-K by October 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. congratulates JV partner Virion Therapeutics, on presenting first-ever human data for novel checkpoint modifier immunotherapy for HBV functional cure at APASL 2024. The Phase 1 data of VRON-0200 showed safety and tolerability in HBV-infected patients. Virion's CEO, Dr. Andrew Luber, highlighted the potential of VRON-0200 and other pipeline programs, aiming to revolutionize immunotherapy for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) congratulates joint venture partner, Virion Therapeutics, LLC, for their abstract acceptance at APASL's 33rd Annual Meeting, presenting first-ever human data on HBV immunotherapy. The presentation will focus on safety data from ongoing Phase 1B clinical trial of VRON-0200, a novel checkpoint modifier T cell vaccine designed for HBV functional cure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
conferences clinical trial
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced new findings in the peer-reviewed journal Immunity detailing the role of CHI3L1 in the growth of triple negative breast cancer. The research demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from killing the tumor. Ocean's anti-CHI3L1 antibody shows potential in reversing this process and suppressing breast cancer tumor growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) received a notice from Nasdaq stating non-compliance with filing its quarterly report on Form 10-Q for the period ended September 30, 2023. The company is delayed in filing due to an interpretation of SEC accounting guidance for certain Forward Purchase Agreements. Ocean Biomedical has to submit a plan by January 22, 2024, to regain compliance and file the delinquent Form 10-Q by May 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced that its joint venture partner, Virion Therapeutics, presented compelling preclinical oncology data at SITC 2023, demonstrating complete tumor clearance and a 10-fold increase in T cell responses. Virion is also enrolling their Phase 1b clinical trial for chronic hepatitis B virus with VRON-0200, targeting a $6.5B+ market opportunity by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.36%
Tags
none
Rhea-AI Summary
Ocean Biomedical's joint venture partner, Virion Therapeutics, has dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy for chronic Hepatitis B virus (HBV) infection. VRON-0200, a first-in-class treatment, aims to enhance and broaden a patient's immune response to overcome immune exhaustion. Initial clinical data is expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
-
Rhea-AI Summary
Virion Therapeutics and Ocean Biomedical have announced the dosing of the first patients in the Phase 1b clinical trial of their investigational immunotherapy VRON-0200 for chronic Hepatitis B virus (HBV) infection. The treatment aims to enhance and broaden a patient's immune response to overcome immune exhaustion. Initial clinical data is expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced that its Chief Scientist, Jonathan Kurtis MD, PhD, has received the Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates. The program aims to address the growing resistance to current malaria medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
Rhea-AI Summary
Ocean Biomedical announces enrollment of patients in Phase 1b study for Hepatitis B treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Ocean Biomedical Inc.

Nasdaq:OCEA

OCEA Rankings

OCEA Stock Data

76.18M
3.15M
73.18%
13.72%
2.75%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Providence